Viatris Free Cash Flow 2010-2025 | VTRS
Viatris annual/quarterly free cash flow history and growth rate from 2010 to 2025. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
- Viatris free cash flow for the quarter ending March 31, 2025 was 504.20, a year-over-year.
- Viatris free cash flow for the twelve months ending March 31, 2025 was , a year-over-year.
- Viatris annual free cash flow for 2024 was $1.98B, a 21.97% decline from 2023.
- Viatris annual free cash flow for 2023 was $2.537B, a 2.68% decline from 2022.
- Viatris annual free cash flow for 2022 was $2.607B, a 1.12% increase from 2021.
| Viatris Annual Free Cash Flow | |
|---|---|
| 2024 | 1,979.60 |
| 2023 | 2,537.00 |
| 2022 | 2,606.80 |
| 2021 | 2,578.00 |
| 2020 | 990.90 |
| 2019 | 1,618.50 |
| 2018 | 2,118.90 |
| 2017 | 1,875.60 |
| 2016 | 1,656.80 |
| 2015 | 1,645.60 |
| 2014 | 689.50 |
| 2013 | 797.30 |
| 2012 | 660.00 |
| 2011 | 440.58 |
| 2010 | 743.56 |
| 2009 | 450.67 |
| Viatris Quarterly Free Cash Flow | |
|---|---|
| 2025-03-31 | 504.20 |
| 2024-12-31 | 1,979.60 |
| 2024-09-30 | 4,147.00 |
| 2024-06-30 | 1,564.20 |
| 2024-03-31 | 806.10 |
| 2023-12-31 | 2,537.00 |
| 2023-09-30 | 2,181.40 |
| 2023-06-30 | 1,393.80 |
| 2023-03-31 | 924.10 |
| 2022-12-31 | 2,606.80 |
| 2022-09-30 | 2,571.10 |
| 2022-06-30 | 1,805.40 |
| 2022-03-31 | 1,079.10 |
| 2021-12-31 | 2,578.00 |
| 2021-09-30 | 2,250.10 |
| 2021-06-30 | 1,284.90 |
| 2021-03-31 | 811.80 |
| 2020-12-31 | 990.90 |
| 2020-09-30 | 1,071.60 |
| 2020-06-30 | 584.00 |
| 2020-03-31 | 248.10 |
| 2019-12-31 | 1,618.50 |
| 2019-09-30 | 1,001.70 |
| 2019-06-30 | 532.00 |
| 2019-03-31 | -92.60 |
| 2018-12-31 | 2,118.90 |
| 2018-09-30 | 1,568.20 |
| 2018-06-30 | 976.10 |
| 2018-03-31 | 591.10 |
| 2017-12-31 | 1,875.60 |
| 2017-09-30 | 1,444.00 |
| 2017-06-30 | 942.50 |
| 2017-03-31 | 425.60 |
| 2016-12-31 | 1,656.80 |
| 2016-09-30 | 1,458.20 |
| 2016-06-30 | 376.10 |
| 2016-03-31 | 28.70 |
| 2015-12-31 | 1,645.60 |
| 2015-09-30 | 1,149.20 |
| 2015-06-30 | 259.70 |
| 2015-03-31 | 218.90 |
| 2014-12-31 | 689.50 |
| 2014-09-30 | 676.70 |
| 2014-06-30 | 299.20 |
| 2014-03-31 | 195.80 |
| 2013-12-31 | 797.30 |
| 2013-09-30 | 450.20 |
| 2013-06-30 | 148.30 |
| 2013-03-31 | 34.50 |
| 2012-12-31 | 660.00 |
| 2012-09-30 | 514.38 |
| 2012-06-30 | 96.68 |
| 2012-03-31 | -142.82 |
| 2011-12-31 | 440.58 |
| 2011-09-30 | 260.26 |
| 2011-06-30 | 31.93 |
| 2011-03-31 | -86.92 |
| 2010-12-31 | 743.56 |
| 2010-09-30 | 645.63 |
| 2010-06-30 | 305.84 |
| 2010-03-31 | 220.52 |
| 2009-12-31 | 450.67 |
| 2009-09-30 | 463.42 |
| 2009-06-30 | 283.21 |
| 2009-03-31 | 95.23 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $10.293B | $14.739B |
| Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $139.155B | 26.10 |
| Elevance Health (ELV) | United States | $84.931B | 10.96 |
| CVS Health (CVS) | United States | $84.554B | 10.51 |
| Cencora (COR) | United States | $57.517B | 20.01 |
| Natera (NTRA) | United States | $23.347B | 0.00 |
| DiDi Global (DIDIY) | China | $22.403B | 23.80 |
| Labcorp Holdings (LH) | United States | $21.878B | 17.75 |
| BioMerieux (BMXMF) | France | $16.861B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $13.676B | 0.00 |
| Solventum (SOLV) | United States | $12.566B | 13.30 |
| CochLear (CHEOY) | Australia | $12.083B | 0.00 |
| ICON (ICLR) | Ireland | $11.595B | 10.78 |
| Revvity (RVTY) | United States | $11.128B | 19.15 |
| Doximity (DOCS) | United States | $10.714B | 49.60 |
| Avantor (AVTR) | United States | $9.056B | 13.16 |
| HealthEquity (HQY) | United States | $8.820B | 38.64 |
| Medpace Holdings (MEDP) | United States | $8.700B | 23.11 |
| Sonic Healthcare (SKHHY) | Australia | $8.407B | 0.00 |
| Charles River Laboratories (CRL) | United States | $7.136B | 13.98 |
| Amplifon S.p.A (AMFPF) | Italy | $5.378B | 29.44 |
| Bausch + Lomb (BLCO) | Canada | $4.085B | 24.06 |
| BrightSpring Health Services (BTSG) | United States | $3.934B | 36.10 |
| Sotera Health (SHC) | United States | $3.105B | 17.65 |
| Alignment Healthcare (ALHC) | United States | $2.849B | 0.00 |
| Concentras Parent (CON) | United States | $2.676B | 15.47 |
| Organon (OGN) | United States | $2.568B | 2.73 |
| Surgery Partners (SGRY) | United States | $2.542B | 33.06 |
| PACS (PACS) | United States | $2.027B | 0.00 |
| Progyny (PGNY) | United States | $1.856B | 40.85 |
| Ardent Health (ARDT) | United States | $1.854B | 7.90 |
| GeneDx Holdings (WGS) | United States | $1.838B | 70.80 |
| Premier (PINC) | United States | $1.834B | 13.92 |
| GoodRx Holdings (GDRX) | United States | $1.600B | 32.00 |
| Teladoc Health (TDOC) | United States | $1.230B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.147B | 8.73 |
| Establishment Labs Holdings (ESTA) | $1.100B | 0.00 | |
| CareDx (CDNA) | United States | $1.060B | 16.55 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.011B | 0.00 |
| Agilon Health (AGL) | United States | $0.902B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.856B | 8.01 |
| QDM (QDMI) | Hong Kong, SAR China | $0.758B | 0.00 |
| LifeMD (LFMD) | United States | $0.684B | 0.00 |
| Nutex Health (NUTX) | United States | $0.661B | 10.01 |
| Embecta (EMBC) | United States | $0.569B | 3.83 |
| InnovAge Holding (INNV) | United States | $0.512B | 0.00 |
| SBC Medicals (SBC) | United States | $0.482B | 0.00 |
| Enhabit (EHAB) | United States | $0.473B | 38.92 |
| Auna S.A (AUNA) | Luxembourg | $0.459B | 10.33 |
| Sonida Senior Living (SNDA) | United States | $0.454B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.449B | 0.00 |
| Omada Health (OMDA) | $0.399B | 0.00 | |
| Performant Healthcare (PHLT) | United States | $0.267B | 0.00 |
| Oncology Institute (TOI) | United States | $0.212B | 0.00 |
| Beauty Health (SKIN) | United States | $0.184B | 0.00 |
| DocGo (DCGO) | United States | $0.165B | 27.00 |
| Pheton Holdings (PTHL) | China | $0.119B | 0.00 |
| So-Young (SY) | China | $0.102B | 0.00 |
| KindlyMD (NAKA) | United States | $0.084B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.071B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.059B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.053B | 0.00 |
| ModivCare (MODV) | United States | $0.052B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.049B | 0.00 |
| Biodesix (BDSX) | United States | $0.040B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.034B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.013B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.011B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.009B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| INVO Fertility (IVF) | United States | $0.003B | 0.00 |
| ISpecimen (ISPC) | United States | $0.002B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |